BFN Biofusion

Biofusion PLC
06 September 2007


For immediate release                                           6 September 2007


                                 BIOFUSION PLC

                         ("Biofusion" or "the Company")


              APPOINTMENT OF COMMERCIAL MANAGER FOR FUSION CARDIFF


Biofusion plc (AIM: BFN), the university IP commercialisation company that turns
world class research into business, is pleased to announce that Dr Dominic
Griffiths has been appointed as Commercial Manager for Fusion Cardiff Ltd
("Fusion Cardiff"), a role in which he will focus on commercial opportunities
arising from Cardiff University's intellectual property, with immediate effect.


Fusion Cardiff is the Cardiff University arm of Biofusion that was named as such
to reflect the fact that Biofusion's portfolio of companies has expanded beyond
life sciences.


Prior to joining Biofusion, Dominic spent four years working at Phoqus
Pharmaceuticals, the AIM-listed oral drug delivery company, where he was
Director of Business Development.


Earlier in his career Dominic spent three years at the management consultancy
Cap Gemini Ernst & Young (previously Gemini Consulting) as a Consultant, where
he undertook both strategic analysis and operational improvement projects with
pharmaceutical, agribusiness and biotechnology companies. Prior to CGE&Y he
worked as Consultant at PharmaVentures Ltd, a specialist advisory and
consultancy firm serving the global pharmaceutical industry.



Dominic has a DPhil in Biochemistry from the University of Sussex and has
performed post-doctoral research in both the UK at Imperial Cancer Research Fund
and the USA at Stanford University.


Commenting on this announcement, David Baynes, Chief Executive Officer of
Biofusion, said: "We are delighted that Dominic has joined us at Fusion Cardiff.
His business development experience coupled with management consultancy will
stand him in great stead to manage the commercialisation of our portfolio
companies that have been formed via our long-term partnership with Cardiff
University."


Dr Griffiths, Commercial Manager for Fusion Cardiff, added: "I am excited about
joining the entrepreneurial environment at Fusion Cardiff and am looking forward
to assisting Biofusion's existing portfolio companies and working with the
University's Commercialisation Division to establish new companies arising from
the highly innovative research being undertaken in Cardiff."


For further information please contact:
Biofusion                                                  +44 (0)114 275 5555
David Baynes, CEO

Buchanan Communications                                    +44 (0)20 7466 5000
Lisa Baderoon / Mary-Jane Johnson / Catherine Breen

About Biofusion


Biofusion was established in 2002 to commercialise university-generated IP.
Biofusion has signed long term agreements with two of the UK's top ten research
intensive universities (University of Sheffield and Cardiff University) giving a
combined R&D spend attributable to Biofusion of approximately #114 million a
year. The Company has a portfolio of 24 spin-out companies.


Biofusion's first agreement was a ten-year exclusive arrangement with the
University of Sheffield for the commercialisation of IP owned by the University
in the area of medical life sciences. Biofusion has shareholdings in a portfolio
of 17 Sheffield University spin-out companies including Asterion, Axordia,
Celltran, Lifestyle Choices, Diurnal and Phase Focus. The University of
Sheffield was ranked 5th in the UK for the quality of its life sciences research
and will be spending an estimated #0.5bn of research funding over the lifetime
over the life of the Sheffield Agreement.


In January 2007, Biofusion completed a long-term exclusive agreement with
Cardiff University, to commercialise 100% of all Cardiff University's
research-generated IP. Biofusion has shareholdings in a portfolio of seven
Cardiff University spin-out companies including Abcellute, Q-Chip and Cardiff
Protides. Cardiff University was ranked 7th in the UK in the most recent
research rankings and will be spending over #1.0bn of research funding over the
lifetime over the life of the Cardiff Agreement.






                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
NRAOKPKQOBKDOCK

Biofusion (LSE:BFN)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024

Biofusion (LSE:BFN)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024